COMPANY
Ridgeback Biotherapeutics
Timeline
- Trial start Phase 2: Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 source ↗
- Trial start Phase 2: The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) source ↗
- Trial start Phase 1: COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05067166 | Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP | Not listed | Available | Not listed | Not listed |
| NCT04405739 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | Phase 2 | Completed | Jun 16, 2020 | Feb 21, 2022 (actual) |
| NCT04405570 | Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | Phase 2 | Completed | Jun 19, 2020 | Feb 21, 2021 (actual) |
| NCT04392219 | COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers | Phase 1 | Completed | Apr 10, 2020 | Aug 11, 2020 (actual) |